|
|
|
|
|
|
| To join hands with leading Korean industry player in Developing into an international biopharmaceutical enterprise |
HONG KONG, Dec 16, 2016 - (ACN Newswire) - Tongfang Kontafarma Holdings Limited ("Tongfang Kontafarma" or the "Group"; stock code: 1312.hk), today announced the proposed 29% stake acquisition of Binex Co. Ltd. ("Binex" or the "Target Company"; stock code: 053030.ks), a Korea-listed company engaged in the manufacturing and selling of pharmaceuticals mainly in Korea.
 | | Binex's bio-manufacturing facility in Songdo, Incheon, Korea |
 | | Binex's bio-manufacturing facility in Osong, Korea |
 | | Binex's 5,000-liter cell cultivation line at Osong facility |
On 29 November 2016 (before trading hours), Tongfang Kontafarma entered into a share subscription agreement with Binex and its majority shareholders, pursuant to which the Group has conditionally agreed to subscribe, and the Target Company has conditionally agreed to issue to the Group, the subscription shares, representing (i) approximately 29% of the total issued share capital of the Target Company as enlarged by the subscription shares immediately upon completion of the subscription; and (ii) approximately 28% of the total issued share capital of the Target Company as enlarged by the subscription shares and assuming that all the outstanding convertible bonds and employees share options of the Target Company are fully converted and exercised.
Upon completion, Binex will have a total of 7 directors, 4 of which will be nominated by Tongfang Kontafarma and the remaining 3 will be nominated by the Target Company's original majority shareholders, which will then hold approximately 7.60% of the total issued share capital as enlarged by the subscription shares. The Target Company will be regarded as a non-wholly owned subsidiary of the Group and the financial results, assets and liabilities of the Target Group will be consolidated into the accounts of the Group upon completion. The subscription will constitute a very substantial acquisition of the Group under the HKEx Listing Rules and is therefore subject to reporting, announcement and shareholders' approval requirements.
Mr. Huang Yu, Chairman of the Group, said, "Tongfang Kontafarma will cooperate with Binex to build an international biopharmaceutical industry base. Binex will draw from its extensive experience in building, operating and managing biopharmaceutical production plants to provide technical guidance and comprehensive solutions for the factory project, as well as assign its experienced technical, management and operational staff to work in China to aid the construction of the new factory and later-stage management and operation. We have full confidence in cooperating with Binex."
Binex is a leading Korean biopharmaceutical enterprise and the second largest biopharmaceutical CMO (Contract Manufacturing Organization) company in the country after Samsung. It owns two biopharmaceutical factories, which have passed Korean GMP certification, the European Qualified Person (QP) audit and the even more stringent on-site audits by international pharmaceutical giants such as Merck Sereno, MSD and Sanofi. It has completed over 200 batches of biopharmaceutical products, with the support of its full range of world-class GMP manufacturing facilities and strong industrialization ability. It has a pool of products which have completed or are undergoing stage II & III clinical trials in Japan, the U.S. and Europe. In particular, it has one drug, Remicade biosimilar, that has completed clinical III trial in Japan and is awaiting final approval from PMDA (Pharmaceuticals and Medical Device Agency (Japan)). Final approval is expected in the first half of 2017.
Mr. Huang concluded, "Tongfang Kontafarma has been cooperating with a few dozen experienced scientists specializing in biopharmaceutical R&D from the School of Pharmaceutical Sciences, School of Medicine and School of Life Sciences of Tsinghua University to build a world leading R&D platform for innovative biomedicines. It will apply Binex's leading biopharmaceutical technologies and experience to build an "industry-academia-research" integrated biopharmaceutical industry chain. This latest acquisition will allow the Group to establish presence in the international biopharmaceutical sector, as well as tap Binex's rich international CMO customer resources and business experience to speed up international authorization for the Group's innovative biomedicines under development and foster development of the international CMO business of its industrial base. The acquisition will give the Group a solid foundation to develop into a world leading international biopharmaceutical company that focuses on innovation and industrialization. We are excited about the proposed acquisition of Binex as it represents a key milestone of Tongfang Kontafarma's development into a regional pharmaceutical and healthcare enterprise."
Contact:
Strategic Financial Relations Limited
Cindy Lung / Sophie Du
Tel: (852) 2864 4867 / 2114 4901
Email: cindy.lung@sprg.com.hk / sophie.du@sprg.com.hk
www.sprg.asia
Topic: Press release summary
Source: Tongfang Kontafarma Holdings Limited
Sectors: Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Smart Ways to Organise Payments for Better Rewards and Everyday Savings
May 11, 2026 14:00 HKT/SGT
|
|
|
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals
May 8, 2026 23:00 HKT/SGT
|
|
|
Sydney and Melbourne kick off ninth edition of PropertyGuru Asia Property Awards in Australia 
May 8, 2026 14:40 HKT/SGT
|
|
|
How to Travel More Often Without Increasing Your Budget
May 8, 2026 13:00 HKT/SGT
|
|
|
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare
May 7, 2026 20:30 HKT/SGT
|
|
|
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
May 7, 2026 20:00 HKT/SGT
|
|
|
Focus Graphite Announces One of the Largest Identified Graphite Deposits Globally at the Lac Tetepisca Project
May 7, 2026 17:29 HKT/SGT
|
|
|
Nissin Foods Forms Joint Capital Investment with Itochu HK to Strengthen Distribution Platforms in PRC Markets
May 7, 2026 16:55 HKT/SGT
|
|
|
Fujitsu Digitalizes Management of Japan's Reserve Self-Defense Force for Ministry of Defense, Enhancing Efficiency
Thursday, May 7, 2026 1:02:00 PM
|
|
|
Neat Appoints Javed Khan as CEO to Lead AI Transformation
May 7, 2026 12:53 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
|
|
|
 |
|
